Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain

Completed

Conditions studied: Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II

In brief

An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).

Key facts

Study ID

NCT06632730

Run by

Novartis

People needed

69

Starts

2023-07-05

Expected to finish

2023-11-20

Last updated by the study team

2024-10-09

Who can join

Age: any, up to 14. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with SMA type I or SMA type II.
• Patients with medical records available in the hospital.
• Patients diagnosed with SMA type I or SMA type II after 2017 for whom a minimum of 6 months of follow-up was available.

You may not qualify if…

• Patients who participated in an experimental design study except for those in the long-term follow-up period, during the observation period.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.